REALATED ARTICLES

Click on a word or phrase in our Tag Cloud and see all related articles listed below.

 

Current tag:

Roche Ethiopia: Build-up of an emerging market

Awasa College of Medicine23-01-2012. In a move to strengthen its foothold in East Africa, the Swiss pharma and diagnostics company is accelerating a major program to offer patients access to its products, educate health professionals, and recruit patients. A report by Bikila Wolde on Roche's plans and prospects.

 

 

Related Articles

The Global Dimension of EU Health and Food Policies

Paola Testori-Coggi, Director-General for Health and Consumers, European Commission

FAO: Major shifts expected in operations

No Mercy with Violators of Corporate Compliance

Dr Rüdiger Scheitza, Member of the Board Bayer CropScience, and Labour Director on ensuring governance and compliance around the world - developing countries included.

Stem Cells: a discovery tool and a potential therapeutic modality

Prof. Jonathan Knowles, Former Member of the Roche Executive Committee and Head of Group Research

Bayer AG: New Stakes in Stem Cells

Prof. Andreas Busch, Member of the Bayer HealthCare Executive Committee, responsible for Global Drug Discovery

Jimmy Smith moves from World Bank to ILRI Kenya

Roche supports cancer care development program in Ethiopia

Corporate Press Release, 23-01-2012



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

2 pages; advert-free

COSMO: Positive results of first parts of Phase II / Blu-colonscopy

20-06-2011. Cosmo Pharmaceuticals S.p.A. today announced that a live transmission of a colonoscopy on a patient that had taken a Methylene Blue MMX® tablet for the better diagnosis of polyps, dysplastic lesions and adenomas in the colon, took place in front of approximately 500 specialists from around the world present at the International Meeting for Advanced Gastroenterology Endoscopy at Humanitas Hospital in Milano/Italy. Separately Prof Repici of Humanitas Hospital, who is conducting the phase II dose ranging trial testing the colon staining efficacy of single increasing oral doses of Methylene Blue MMX modified release tablets, gave a preliminary analysis of the results from the first 40 patients that have been treated so far.  
 
Prof. Repici said, “The preliminary results of the phase II dose ranging study convincingly demonstrate Methylene blue-MMX®tablet’s ability to stain the entire colon and thus vastly increase the possibility of detecting small polyps, dysplastic lesions and adenomas. It is of utmost importance to detect these small polyps, lesions and adenomas as early as possible before they turn into cancer, also considering that every colon cancer patient costs between USD 35’000 and USD 85’000 per year. The results that have been achieved in my study point out that Methylene blue-MMX®could become the diagnostic of choice for every screening colonoscopy.”
 
The Methylene blue-MMX®tablet is an oral colon-release formulation in form of coated tablets, containing methylene blue. The tablets are formulated using Cosmo’s patented multimatrix technology (MMX®) that allows the delivery of the active ingredient directly inside the colon. With this technology, the maximum local bioavailability of the active ingredient is achieved and, consequently, the biological effect is optimized. Patents have been filed and are pending.
 
Provepharm SAS, France is the manufacturer of Proveblue™, the methylene blue powder used in Methylene blue-MMX® tablets. The active ingredient in the powder is manufactured in compliance with European Pharmacopoeia. Unlike other manufacturers the powder obtained at Provepharm reaches a purity grade of 99%. Cosmo and Provepharm have entered into an exclusive licensing agreement.
 
The phase II dose ranging study that is being conducted by Prof A. Repici at the Istituto Clinico Humanitas in Rozzano/Italy is designed to treat approximately 100 patients undergoing colonoscopy with single increasing oral doses of Methylene Blue MMX modified release tablets with the intention of testing the colon staining efficacy. It is scheduled to be completed in the second half of the year.

 

__________________

Disclaimer: You agree that  B2Bioworld is not responsible and will not be held liable for any third party content on its sites or any third-party content, products or services available on other web sites accessed through links from  B2Bioworld sites. Links to third-party sites are for your convenience only, and their inclusion on   B2Bioworld's sites does not imply any endorsement, guarantee, warranty or representation by B2Bioworld.

___________________

 

Provepharm: Synthetic Scheme for Methylene Blue

by B2Bioworld Editor* 

Source: US0291943, 26-11-09

 

 

* A non-sponsored service for free to readers of B2Bioworld - Get out more of PR

 


Bayer AG: New Stakes in Stem Cells

Prof. Andreas Busch, Member of the Bayer HealthCare Executive Committee, responsible for Global Drug Discovery

Prof. Andreas BuschJanuary 2011. An unmasked account of decisions about investing into cancer stem cell research and the fate of regenerative medicine projects in Japan. Dr Busch summarises results and evaluates technology platforms like novel antibodies and wnt mechanisms. He voices his expectations from current key drug development partnerships, in particular with Oncomed and Micromet. Will these include companion diagnostics? To what extent does Bayer retain respective intellectual property rights? A comment on personalised medicine and cancer stem cells research pursued by Merck KGaA and others. What are prospects for classic oncology drugs?

 

 

 

Related Articles

Horizon Discovery: Mitigating risks and developing the U.S. business

Tasks ahead for Eric Rhodes, the new CTO

Roche Ethiopia: Build-up of an emerging market

Systems Biology: In search of good questions

Prof Walter Kolch on the approach taken by Systems Biology Ireland


B2Bioworld Stem Cell Insights Collection 2010:

Issues and Evaluation from Pharma Leaders

 

Dr Patrick Vallance, GSK:

Stem Cell Research Now and in the Future

 

No Mercy with Violators of Corporate Compliance

Dr Rüdiger Scheitza, Member of the Board Bayer CropScience, and Labour Director

 



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

3 pages, exclusive

P.Vallance, GSK: Stem Cell Research Now and in the Future

(C) Dr Patrick Vallance 2008November 2009. “Stem cells provide novel opportunities that didn't previously exist” says Dr Patrick Vallance, Head of GlaxoSmithKline’s Drug Discovery in an interview with B2Bioworld. He describes his company’s approach. What is the role of cancer stem cells? What about novel drugs like lapatinib or trastuzumab? Which collaborations are desirable? The report includes stem cell issues yet unattended by pharma.



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

exclusive interview 3 pages

Clear away complete confusion of terms - The case of stem cell research

Dr Bernhard Kirschbaum (C) Wolf G Kroner 2009 February 2009. While many ethical questions surrounding the use of stem cells have been satisfactorily answered, a number of unresolved methodological and technical issues hamper applications in the pharmacceutical industry. Where are the stumbling blocks of today? What is Merck’s and Merck Serono’s approach, and with what prospects?

 

 

Related Articles

Bayer AG: New Stakes in Stem Cells

Prof. Andreas Busch, Member of the Bayer HealthCare Executive Committee, responsible for Global Drug Discovery

The Myriad Way

Peter D Meldrum, CEO of the genetics company on battles about patents, cancer chips, and competitors in commercial academia

Stem Cells - Failings and Deliveries

Towards Pharma Standards for Assays: Drug Testing with Embryonic Stem Cells

 

 

or access the complete Stem Cell Insights Collection



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

exclusive interview, 2 pages

Top 10 Tags

All Tags (2094)